Eli Lilly to Acquire Merida Biosciences for $2.875 Billion to Boost Immunology

Key Facts

In a move reflecting the accelerating pace of healthcare consolidation to develop next-generation treatments, Eli Lilly has announced a definitive agreement to acquire Merida Biosciences. This acquisition aims to integrate Merida’s antibody-engineering platform into Lilly’s immunology portfolio, focusing on the precise removal of disease-causing antibodies. According to reports, initial Phase 1 data for Merida's lead program, MER511, demonstrated robust reductions in pathogenic antibodies with a favorable initial safety profile.

The transaction, valued at up to $2.875 billion including upfront and milestone-based payments, strengthens Lilly’s capabilities in treating conditions such as Graves' disease and thyroid eye disease. Merida utilizes a platform designed to preserve normal immune function while selectively eliminating harmful autoantibodies. Per market data, such strategic moves highlight the drive among mega-cap pharmaceutical firms to expand drug pipelines within high-growth immunology markets.

Regarding stock performance, LLY stood at $1174.61 (close August 28, 2026), having reached a day high of $1180. Investors should watch for the final closing of the transaction and its subsequent accounting treatment. While the current economic calendar shows no immediate sector-specific catalysts in the coming days, clinical progress regarding the MER511 program remains a primary focal point for long-term growth.